Translational research of IL-6 biology into therapies targeting its pivotal pathway has been progressing for more than a decade, and IL-6 inhibitors have been shown to be effective in treatments of chronic arthritis (JIA), Takayasu arteritis and giant cell arteritis (GCA), cytokine release syndrome (CRS), and other severe diseases (Choy et al., 2020). The gene discussed is IL6; the disease is temporal arteritis.